Navigation Links
Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/9/2013

SAN DIEGO, May 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.  

The live presentation takes place on Thursday, May 16 at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600 or ir@neurocrine.com.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for one month.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
2. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
3. Neurocrine Biosciences Reports Third Quarter 2012 Results
4. Neurocrine Biosciences Reports Second Quarter 2012 Results
5. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
6. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
7. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
10. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
11. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Aratana Therapeutics, Inc. (NASDAQ: PETX ... development and commercialization of innovative biopharmaceutical products for companion ... North America 2016. ... on the FDA approval of three innovative therapeutics in ... (capromorelin oral solution) and NOCITA ® (bupivacaine liposome ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
Breaking Biology Technology:
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
Breaking Biology News(10 mins):